Status:
RECRUITING
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
Lead Sponsor:
Emory University
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
Detailed Description
PRIMARY OBJECTIVES: I. Evaluate the association between pre-treatment diversity of the fecal microbiome and major pathological response to neoadjuvant chemotherapy in operable pancreatic ductal adeno...
Eligibility Criteria
Inclusion
- \* Age ≥ 18 years with signed informed consent form
- Patients must have a histological diagnosis of PDAC
- Resectable or borderline resectable PDAC on imaging
Exclusion
- \* Patients with locally advanced and metastatic stage IV PDAC
- Patients who have already received or completed neoadjuvant chemotherapy for PDAC
- Patients with active malignancy receiving systemic therapy
Key Trial Info
Start Date :
August 5 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 7 2027
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT06595160
Start Date
August 5 2024
End Date
August 7 2027
Last Update
August 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States, 30322